search
Back to results

Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN)

Primary Purpose

Fetal Growth Restriction

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Trans-cervical balloon
Misoprostol
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fetal Growth Restriction focused on measuring Fetal growth restriction, Cesarean section, Induction of labor, Cervical ripening, Neonatal morbidity

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Age over 18 years Singleton gestation, with cephalic presentation Gestational age at randomization between entre 34 weeks of gestation and 0 day and 41 weeks of gestation and 0 day Fetal growth restriction (FGR). FGR is defined at the third trimester by an abdominal circumference below the 10th centile and/or an estimated fetal weight below the 10th centile (according to local curve), according to the trial DIGITAT. Fetus with normal and abnormal Doppler index can be included. Plan for induction of labor whatever the indication (fetal growth restriction or other), the induction of labor is the induction of birth by vaginal delivery Bishop Score below 6 Affiliated or beneficiary to a health security system Signed informed consent Exclusion Criteria: Contraindication to an induction of labor History of previous cesarean delivery, myomectomy by laparotomy or laparoscopy Contraindication to misoprostol or trans-cervical balloon Known HIV positivity (because of modified delivery plan) Known major fetal anomaly or chromosomic anomaly Fetal demise Patient under legal protection Poor understanding of the French language

Sites / Locations

  • CHU Bordeaux

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Trans-cervical balloon

Misoprostol

Arm Description

Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter)

Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)

Outcomes

Primary Outcome Measures

cesarean section
Incidence of cesarean section defined as a cesarean birth regardless of the indication

Secondary Outcome Measures

duration of labor
Mean duration of labor (duration between admission to the labor room and delivery)
duration between cervical ripening and delivery
Mean duration between cervical ripening and delivery
oxytocin use
Incidence of oxytocin use (median of the maximal administered dosage)
operative delivery
Incidence of operative delivery (vacuum, forceps, spatula)
postpartum hemorrhage
Incidence of postpartum hemorrhage defined by blood loss >500mL (defined according to the CNGOF criteria)
Mean total blood loss
Mean total blood loss (mL)
intra-uterine infectious
Incidence of intra-uterine infectious defined by a fever (maternal temperature equal to or greater than 38°C twice), associated to at least one of the two criterion: persistent fetal tachycardia > 160 bpm, or purulent amniotic fluid (defined according to the CNGOF criteria).
iron administration
Incidence of postpartum intravenous iron administration
transfusion
Incidence of transfusion of blood products or blood
maternal thromboembolism event
Incidence of maternal thromboembolism event (deep venous thrombosis diagnosed using leg Doppler ultrasound or pulmonary embolism diagnosed using computed tomographic pulmonary angiography)
maternal satisfaction
Incidence of maternal satisfaction with a satisfaction questionnaire derived from the childbirth experience questionnaire and satisfaction questionnaire of TRAAP2 study
Mean duration of hospitalization
Mean duration of hospitalization
umbilical artery lactic acid
Incidence of umbilical artery lactic acid greater than 10mmol/l
umbilical artery pH
Incidence of umbilical artery pH of less than 7,05
neonatal Apgar Score
Incidence of neonatal 5 minutes Apgar Score of less than 7
neonatal hypoglycemia
Incidence of neonatal hypoglycemia (blood glucose < 35 mg/L) requiring intravenous therapy
neonatal intensive care
Incidence of admission to neonatal intensive care unit or intermediate care unit
neonatal length of hospital stay
Mean neonatal length of hospital stay
neonatal death before discharge
Incidence of neonatal death before discharge
non-reassuring fetal status
Incidence of non-reassuring fetal status occurring after the beginning of the cervical ripening (including both cervical ripening and labor). Non-reassuring fetal status is defined by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO), who class the CTG tracing in 3 class: normal, suspicious and pathological 3. According to this classification, non-reassuring fetal status is defined as the presence of a suspicious or pathological CTG tracings, predictive of hypoxia/ neonatal acidosis status
cesarean section for non-reassuring fetal status
Incidence of cesarean section for non-reassuring fetal status
cesarean section for arrest of labor
Incidence of cesarean section for arrest of labor
neonatal ventilation
Incidence of the need for neonatal ventilation in the first 72 hours of life, defined by intubation, continuous positive airway pressure (CPAP) or high-flow nasal cannula
neonatal hypoxic-ischemic encephalopathy
Incidence of neonatal hypoxic-ischemic encephalopathy
neonatal seizure
Incidence of neonatal seizure
neonatal infection
Incidence of neonatal infection (confirmed sepsis or pneumonia)
neonatal meconium aspiration syndrome
Incidence of neonatal meconium aspiration syndrome,
birth trauma
Incidence of birth trauma (bone fracture, neurologic injury, or retinal hemorrhage),
neonatal intracranial or subgaleal hemorrhage
Incidence of neonatal intracranial or subgaleal hemorrhage,
neonatal arterial hypotension
Incidence of neonatal arterial hypotension requiring pressor support

Full Information

First Posted
April 27, 2023
Last Updated
April 27, 2023
Sponsor
University Hospital, Bordeaux
search

1. Study Identification

Unique Protocol Identification Number
NCT05848869
Brief Title
Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction
Acronym
PROBIN
Official Title
Prostaglandins Versus Trans-Cervical Balloon for Induction of Labor in Fetal Growth Restriction: a Multicenter Open-label Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
September 1, 2025 (Anticipated)
Study Completion Date
September 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this randomized trial is to compare two methods of induction in a fetal growth restriction population. The main question it aims to answer is: • Is trans-cervical balloon superior to prostaglandins in reducing the cesarean section rate, without increasing neonatal morbidity? Participants will have an induction of labour by cervical ripening with trans-cervical balloon in the trans-cervical balloon catheter arm and with Prostaglandins in the Misoprostol arm. Researchers will compare two methods of induction: trans-cervical balloon and prostaglandins to see if trans-cervical balloon is associated with a lower risk of cesarean delivery.
Detailed Description
Fetal growth restriction (FGR) is associated with increased perinatal morbidity and mortality in late pregnancy. Because of this higher risk of adverse perinatal outcome, induction of labor is often proposed and require cervical ripening when the cervix is not favorable, i.e. Bishop score less than 6. Two methods of cervical ripening are currently available and used: pharmacological (prostaglandins) and mechanical (trans-cervical balloon). Growth-restricted fetuses are a population at increased risk for non-reassuring fetal status and hypoxia during labor because of their lower weight. Prostaglandins can lead to cardiotocograph (CTG) tracing abnormalities by causing uterine tachysystole in normal-weight fetuses. Nevertheless, the question of the method of induction of labor has been poorly studied in the population of growth-restricted fetuses. None of the national and international societies reports in their guidelines which method of induction of labor should be offered to pregnancies complicated by a fetal growth restriction. A few retrospective studies are in favor of an increased risk of uterine tachysystole with consequences on the CTG tracing in the case of cervical ripening with prostaglandins compared to the trans-cervical balloon. However, the results of these studies lack robustness due to important methodological limitations. Because trans-cervical balloon is a mechanical method of cervical ripening, it may be less likely to cause uterine tachysystole and thus fewer non-reassuring fetal status. Thus, the risk of cesarean section in labor could be decreased compared with the use of prostaglandins in the growth-restricted fetal population. To date, there is no published quality randomized controlled trials on the optimal method of cervical ripening in induction of labor for FGR fetuses. The present large-scale randomized trial aim to define the preferred method of induction for these fetuses, associated with a lower risk of cesarean delivery. If it is demonstrated that one method of induction (trans-cervical balloon) is superior to another (prostaglandins) in reducing the cesarean section rate, without increasing neonatal morbidity, the results of our study are likely to lead to changes in national and international recommendations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fetal Growth Restriction
Keywords
Fetal growth restriction, Cesarean section, Induction of labor, Cervical ripening, Neonatal morbidity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
774 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Trans-cervical balloon
Arm Type
Experimental
Arm Description
Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter)
Arm Title
Misoprostol
Arm Type
Active Comparator
Arm Description
Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
Intervention Type
Device
Intervention Name(s)
Trans-cervical balloon
Intervention Description
Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
Intervention Type
Drug
Intervention Name(s)
Misoprostol
Intervention Description
Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
Primary Outcome Measure Information:
Title
cesarean section
Description
Incidence of cesarean section defined as a cesarean birth regardless of the indication
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
duration of labor
Description
Mean duration of labor (duration between admission to the labor room and delivery)
Time Frame
Day 1
Title
duration between cervical ripening and delivery
Description
Mean duration between cervical ripening and delivery
Time Frame
Day 1
Title
oxytocin use
Description
Incidence of oxytocin use (median of the maximal administered dosage)
Time Frame
Day 1
Title
operative delivery
Description
Incidence of operative delivery (vacuum, forceps, spatula)
Time Frame
Day 1
Title
postpartum hemorrhage
Description
Incidence of postpartum hemorrhage defined by blood loss >500mL (defined according to the CNGOF criteria)
Time Frame
Day 3
Title
Mean total blood loss
Description
Mean total blood loss (mL)
Time Frame
Day 3
Title
intra-uterine infectious
Description
Incidence of intra-uterine infectious defined by a fever (maternal temperature equal to or greater than 38°C twice), associated to at least one of the two criterion: persistent fetal tachycardia > 160 bpm, or purulent amniotic fluid (defined according to the CNGOF criteria).
Time Frame
Day 5
Title
iron administration
Description
Incidence of postpartum intravenous iron administration
Time Frame
Day 5
Title
transfusion
Description
Incidence of transfusion of blood products or blood
Time Frame
Day 5
Title
maternal thromboembolism event
Description
Incidence of maternal thromboembolism event (deep venous thrombosis diagnosed using leg Doppler ultrasound or pulmonary embolism diagnosed using computed tomographic pulmonary angiography)
Time Frame
Day 5
Title
maternal satisfaction
Description
Incidence of maternal satisfaction with a satisfaction questionnaire derived from the childbirth experience questionnaire and satisfaction questionnaire of TRAAP2 study
Time Frame
Day 5
Title
Mean duration of hospitalization
Description
Mean duration of hospitalization
Time Frame
Day 5
Title
umbilical artery lactic acid
Description
Incidence of umbilical artery lactic acid greater than 10mmol/l
Time Frame
Day 1
Title
umbilical artery pH
Description
Incidence of umbilical artery pH of less than 7,05
Time Frame
Day 1
Title
neonatal Apgar Score
Description
Incidence of neonatal 5 minutes Apgar Score of less than 7
Time Frame
Day 1
Title
neonatal hypoglycemia
Description
Incidence of neonatal hypoglycemia (blood glucose < 35 mg/L) requiring intravenous therapy
Time Frame
Day 5
Title
neonatal intensive care
Description
Incidence of admission to neonatal intensive care unit or intermediate care unit
Time Frame
Day 5
Title
neonatal length of hospital stay
Description
Mean neonatal length of hospital stay
Time Frame
Day 5
Title
neonatal death before discharge
Description
Incidence of neonatal death before discharge
Time Frame
Day 1 to Month 2
Title
non-reassuring fetal status
Description
Incidence of non-reassuring fetal status occurring after the beginning of the cervical ripening (including both cervical ripening and labor). Non-reassuring fetal status is defined by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO), who class the CTG tracing in 3 class: normal, suspicious and pathological 3. According to this classification, non-reassuring fetal status is defined as the presence of a suspicious or pathological CTG tracings, predictive of hypoxia/ neonatal acidosis status
Time Frame
Day 1
Title
cesarean section for non-reassuring fetal status
Description
Incidence of cesarean section for non-reassuring fetal status
Time Frame
Day 1
Title
cesarean section for arrest of labor
Description
Incidence of cesarean section for arrest of labor
Time Frame
Day 1
Title
neonatal ventilation
Description
Incidence of the need for neonatal ventilation in the first 72 hours of life, defined by intubation, continuous positive airway pressure (CPAP) or high-flow nasal cannula
Time Frame
Day 3
Title
neonatal hypoxic-ischemic encephalopathy
Description
Incidence of neonatal hypoxic-ischemic encephalopathy
Time Frame
Day 1 to Month 2
Title
neonatal seizure
Description
Incidence of neonatal seizure
Time Frame
Day 1
Title
neonatal infection
Description
Incidence of neonatal infection (confirmed sepsis or pneumonia)
Time Frame
Day 1 to Day 28
Title
neonatal meconium aspiration syndrome
Description
Incidence of neonatal meconium aspiration syndrome,
Time Frame
Day 5
Title
birth trauma
Description
Incidence of birth trauma (bone fracture, neurologic injury, or retinal hemorrhage),
Time Frame
Day 5
Title
neonatal intracranial or subgaleal hemorrhage
Description
Incidence of neonatal intracranial or subgaleal hemorrhage,
Time Frame
Day 5
Title
neonatal arterial hypotension
Description
Incidence of neonatal arterial hypotension requiring pressor support
Time Frame
Day 1

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age over 18 years Singleton gestation, with cephalic presentation Gestational age at randomization between entre 34 weeks of gestation and 0 day and 41 weeks of gestation and 0 day Fetal growth restriction (FGR). FGR is defined at the third trimester by an abdominal circumference below the 10th centile and/or an estimated fetal weight below the 10th centile (according to local curve), according to the trial DIGITAT. Fetus with normal and abnormal Doppler index can be included. Plan for induction of labor whatever the indication (fetal growth restriction or other), the induction of labor is the induction of birth by vaginal delivery Bishop Score below 6 Affiliated or beneficiary to a health security system Signed informed consent Exclusion Criteria: Contraindication to an induction of labor History of previous cesarean delivery, myomectomy by laparotomy or laparoscopy Contraindication to misoprostol or trans-cervical balloon Known HIV positivity (because of modified delivery plan) Known major fetal anomaly or chromosomic anomaly Fetal demise Patient under legal protection Poor understanding of the French language
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hanane Bouchghoul, MD
Phone
+335 57 82 16 12
Email
hanane.bouchghoul@chu-bordeaux.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Loïc Sentilhes, MD, PhD
Email
loic.sentilhes@chu-bordeaux.fr
Facility Information:
Facility Name
CHU Bordeaux
City
Bordeaux
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hanane Bouchghoul, MD
Phone
+335 56 79 55 79
Email
hanane.bouchghoul@chu-bordeaux.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction

We'll reach out to this number within 24 hrs